Jacob E Berchuck

24PUBLICATIONS
224CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)Molecular targetsCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Apr 16, 2026
Inflammatory biomarkers have a prognostic role in patients with metastatic castration-resistant prostate cancer treated with Lutetium-177-PSMA-617.

|Jan 26, 2026
ctDNA Dynamics and Recurrence Patterns after Organ-Sparing Trimodality Therapy for Bladder Cancer.

Ilana B Epstein, Adetolani Odogiyon, Stephanie Berg

|Feb 19, 2025
Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases.

Jonathan Mitchell, Niedzica Camacho, Patrick Shea

|Nov 04, 2024
Unearthing a Prostate Cancer cfDNA Signature that "Stems" from AR Alterations.

Rashad Nawfal, Razane El Hajj Chehade, Jacob E Berchuck

|Oct 25, 2024
Germline DNA Damage Repair Variants and Prognosis of Patients with High-Risk or Metastatic Prostate Cancer.

Konrad H Stopsack, Joseph Vijai, Michael Conry

|Sep 10, 2024
A panel-based mutational signature of homologous recombination deficiency associates with response to PARP inhibition in metastatic castration-resistant prostate cancer.

Daniel Boiarsky, Alok K Tewari, Doga C Gulhan

Pageof 4

Frequent Collaborators

8 joint publications

Matthew L Freedman

7 joint publications

Toni K Choueiri

6 joint publications

Amin Nassar

5 joint publications

Pier Vitale Nuzzo